clinical trial · NCT04619004
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo·phase2·active not recruiting·n = 277
Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorPatritumab Deruxtecan (Fixed dose)Patritumab Deruxtecan (Up-Titration)
brief summary
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
started
Feb 2, 2021
primary completion
Nov 21, 2022
completion
Jul 3, 2026
last updated
Apr 7, 2026
detailed description
This study will initially randomize participants to one of 2 arms in a 1:1 ratio to receive either a 5.6 mg/kg fixed dose regimen or an up-titration dose regimen of patritumab deruxtecan (HER3-DXd, U3-1402).
official title
HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol